UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-12-12
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of UBT251 injection after 24 weeks of continuous administration in patients with type 2 diabetes mellitus and to recommend the dosing regimen for the Phase III clinical trial.